Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720604 | 0.92 | HTR6 (0.36) | HTR6KMT2ARAB9AATMALDH1A1 | |
| SCHEMBL713695 | 0.86 | KMT2A (0.39) | HTR6KMT2ARAB9AATMALDH1A1 | |
| SCHEMBL715801 | 0.86 | PIK3CG (0.42) | HTR6KMT2ARAB9AATMALDH1A1 | |
| SCHEMBL716114 | 0.84 | NPC1 (0.39) | HTR6KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL470156 | 0.83 | RAB9A (0.36) | HTR6KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL458807 | 0.83 | HTR6 (0.33) | HTR6KMT2ARAB9AATMALDH1A1 | |
| SCHEMBL713738 | 0.82 | RAB9A (0.36) | HTR6KMT2ARAB9AMAPTTP53 | |
| SCHEMBL470076 | 0.82 | HTR6 (0.34) | HTR6KMT2ARAB9AATMALDH1A1 | |
| SCHEMBL470060 | 0.82 | ALDH1A1 (0.39) | HTR6KMT2ARAB9AALDH1A1POLB | |
| SCHEMBL713569 | 0.81 | MAPT (0.34) | HTR6KMT2ARAB9AATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2406255-B1 | 4-OXADIAZOL-2-YL-INDAZOLES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2015-04-29 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | HTR6 1564/4885KMT2A 2534/4885RAB9A 1739/4885 |
| US-20120053166-A1 | 4-Oxadiazol-2-YL-Indazoles as Inhibitors of P13 Kinases | CDK3, CDK13, AKT3 | HTR6 4618/4885KMT2A 3659/4885RAB9A 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.